Ablynx initiates the first of two Phase IIb RA studies with its anti-IL-6R nanobody, partnered with Abbvie

Ablynx announced that it has administered the first dose in the Phase IIb study to evaluate the efficacy and safety of its anti-IL-6R Nanobody®, ALX-0061, administered subcutaneously in combination with methotrexate (MTX) in adult patients with active RA, despite MTX therapy. The study aims to identify the optimum dose and frequency of administration of ALX-0061 for the next phases of development.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Drug development Rheumatology Patient care anti-IL-6R DMARD Latest News methotrexate nanobody rheumatoid arthritis Source Type: news